Efg Asset Management (North America) Corp. Seagen Inc. Transaction History

Efg Asset Management (North America) Corp.

$585 Million
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	SELL	$127.59 - $203.08 $4.97 Million - $7.92 Million	-38,985 Reduced 45.95%	45,855 $9.28 Million
Q4 2022 Feb 03, 2023	BUY	$117.37 - $139.17 $602,577 - $714,498	5,134 Added 6.44%	84,840 $10.9 Million
Q3 2022 Oct 28, 2022	SELL	$135.27 - $180.11 $1.23 Million - $1.64 Million	-9,110 Reduced 10.26%	79,706 $10.9 Million
Q2 2022 Aug 04, 2022	SELL	$108.81 - $179.33 $3.19 Million - $5.26 Million	-29,311 Reduced 24.81%	88,816 $15.7 Million
Q1 2022 Apr 26, 2022	BUY	$119.61 - $157.85 $210,154 - $277,342	1,757 Added 1.51%	118,127 $17 Million
Q4 2021 Feb 18, 2022	BUY	$142.57 - $190.86 $16.6 Million - $22.2 Million	116,370 New	116,370 $18 Million

Others Institutions Holding SGEN

# of Institutions

Shares Held

1.26M

Call Options Held

23K

Put Options Held

55.2K

View Full List

About Seagen Inc.

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

More about SGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Account